For seven years the answer to "is there a GLP-1 pill?" was a qualified yes: one tablet, approved for diabetes, taken on an empty stomach with a mouthful of water and a half hour wait. In 2026 the answer changed twice in four months.
The first change was a higher dose of that same tablet. Oral semaglutide 25 mg, the pill form of Wegovy, was approved for chronic weight management in December 2025 and reached US pharmacies in the new year, carrying the OASIS trial result of about 13.6 percent weight loss over 64 weeks. The second was a different kind of molecule altogether. Orforglipron, approved on April 1, 2026 as Foundayo, is the first GLP-1 receptor agonist that is not a peptide. It is a small molecule that survives the stomach on its own, which means no fasting window, no water limit, and a dose response of about 7.8 to 12.4 percent over 72 weeks in a trial of 3,127 people.
Neither tablet changes the pharmacology that low dose thinking rests on. Both act on the same receptor, both produce the same front loaded dose curve, and both cause the same nausea when pushed. What they change is the practical side: how small a starting dose can be, how precisely it can be held, how much the blood level swings from one day to the next, and what happens to someone who wants a lower exposure phase after an injectable. This article sets out what the trials measured and where a tablet helps or hinders a low dose approach.
Key Takeaways
- Orforglipron, approved by the FDA on April 1, 2026 as Foundayo, is the first non-peptide GLP-1 receptor agonist. In ATTAIN-1, 3,127 adults with obesity without diabetes lost about 7.8 percent at 6 mg, 9.3 percent at 12 mg, and 12.4 percent at 36 mg over 72 weeks, against 0.9 percent on placebo, among those who stayed on treatment.
- Oral semaglutide 25 mg, approved for weight management in December 2025, produced about 13.6 percent weight loss over 64 weeks in OASIS 4 and about 16.6 percent among people who stayed on the tablet, in line with the 14.9 percent seen with the 2.4 mg weekly injection in STEP 1.
- Oral semaglutide has a bioavailability of roughly 1 percent, so a 25 mg daily tablet delivers about 175 mg of semaglutide a week to match a single 2.4 mg injection. That is why the tablet must be taken fasted with no more than about 120 mL of water and a 30 minute wait, and why day to day blood levels vary far more than with an injection.
- Orforglipron has no food, water, or timing restrictions because a small molecule does not need an absorption enhancer. Its half life of roughly one to two days supports once daily dosing with much steadier exposure than oral semaglutide.
- The orforglipron dose curve is front loaded like every other GLP-1: the 6 mg dose delivered about 63 percent of the 36 mg effect. Fixed tablet strengths make low doses easy to prescribe and hold, but neither tablet can be split, so doses between strengths are not available by mouth.
- Gastrointestinal side effects track weight loss rather than route. At the top orforglipron dose, about a third of participants reported nausea and about 10 percent stopped for side effects. Orforglipron showed no liver signal, the concern that ended Pfizer's rival small molecule danuglipron in 2025.
Why was a GLP-1 pill so hard to make?
The stomach is designed to destroy exactly this kind of molecule
GLP-1 pills were hard to make because every GLP-1 receptor agonist before orforglipron is a peptide, and peptides are what the stomach exists to digest. Semaglutide is a chain of 31 amino acids with a fatty acid tail. Swallowed on its own, it is cut apart by pepsin and stomach acid within minutes and almost none reaches the blood. Insulin has the same problem, which is why a century of effort has not produced an insulin tablet. The two ways around this are to protect the peptide long enough for a small fraction to cross the stomach wall, or to abandon the peptide and build a conventional drug molecule that fits the same receptor.
Novo Nordisk took the first route. Oral semaglutide, approved for type 2 diabetes in 2019 as Rybelsus at 7 mg and 14 mg, combines the peptide with 300 mg of an absorption enhancer called SNAC, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate. SNAC raises the pH in a small pocket around the dissolving tablet, which slows pepsin, and it helps semaglutide cross the stomach lining directly. The result is a bioavailability of about 1 percent, and a set of rules to protect that 1 percent: the tablet is taken on waking, on an empty stomach, with no more than about 120 mL of water, and nothing else by mouth for at least 30 minutes. Food or a large glass of water dilutes the SNAC pocket and absorption falls further.
Chugai and Eli Lilly took the second route. Orforglipron is not a peptide at all. It is a small organic molecule, in the same broad chemical family as most tablets in a pharmacy, that was found by screening for compounds that switch on the GLP-1 receptor from a different binding site than the natural hormone uses. Because the stomach has no particular interest in it, orforglipron can be taken at any time with or without food, and its half life of roughly 29 to 49 hours in early studies supports once daily dosing with a relatively flat blood level. The first attempt in this family, Pfizer's danuglipron, was twice daily and was abandoned in April 2025 after a case of drug induced liver injury, which set the bar orforglipron's safety programme had to clear.
How Much Weight Did Orforglipron Produce at Each Dose?
Approximate mean percent body weight loss at 72 weeks in ATTAIN-1, 3,127 adults with obesity or overweight without diabetes, efficacy estimand
Approximate figures in the direction of Wadden and colleagues, New England Journal of Medicine 2025. Under the treatment regimen estimand, which counts everyone regardless of adherence, the top dose figure was about 11.1 percent against 2.1 percent. The step from placebo to 6 mg is worth about 7 points; the six-fold increase from 6 mg to 36 mg is worth another 4.6. The marketed Foundayo tablet uses a different formulation and strength labelling from the trial doses, so trial milligrams do not map one to one onto the pharmacy product.
How does the semaglutide pill compare with the injection?
Same molecule, same result, seventy times the dose
The semaglutide pill matches the injection on weight loss once the dose is high enough to compensate for absorption. In OASIS 1, published in 2023, 667 adults with obesity or overweight without diabetes took oral semaglutide 50 mg daily or placebo for 68 weeks, and the tablet arm lost about 15.1 percent against 2.4 percent. In OASIS 4, published in 2025, 307 adults took a reformulated 25 mg tablet for 64 weeks and lost about 13.6 percent against 2.2 percent, or about 16.6 percent among those who stayed on it. The 25 mg tablet is the one that went to market, because the reformulation delivered roughly the exposure of the older 50 mg tablet at half the dose.
The injection reference point is STEP 1, where semaglutide 2.4 mg weekly produced about 14.9 percent over 68 weeks. The three numbers, 15.1, 13.6 and 14.9, are close enough that the route does not appear to matter for the endpoint. What differs is the amount of drug required. A 2.4 mg weekly injection delivers 2.4 mg of semaglutide. A 25 mg daily tablet delivers 175 mg a week, and the older 50 mg tablet delivered 350 mg. Nearly all of it is destroyed in the stomach, which is harmless but is the reason the pill costs more to manufacture per unit of effect and the reason supply of the injectable was prioritised for years.
The older Rybelsus doses tell the low dose part of the story. At 14 mg daily, the highest diabetes dose, the PIONEER trials found weight loss of about 4.4 kg over 26 weeks in people with type 2 diabetes, roughly 4 to 5 percent of body weight, alongside an A1c reduction of about 1.1 to 1.4 percentage points. That is a meaningful metabolic effect from a tablet that delivers roughly a tenth of the exposure of the weight management dose, and it is the same front loaded shape that appears in every GLP-1 dose curve.
How Does Oral Semaglutide Compare Across Doses and With the Injection?
Approximate mean percent weight loss in the most relevant published trial for each dose, with trial duration in weeks
Not a head to head comparison. The 14 mg figure comes from a 26 week diabetes trial, PIONEER 1, and is converted from kilograms, while the other three are 64 to 68 week weight management trials in people without diabetes. The point is the shape: a tenth of the exposure produced roughly a third of the effect, and doubling from 25 mg to 50 mg added little.
How Much Semaglutide Does Each Route Deliver Per Week?
Milligrams of semaglutide swallowed or injected per week at the approved weight management doses, before absorption
The 2.4 mg bar is barely visible at this scale, which is the point. Roughly 99 percent of an oral semaglutide dose never reaches the blood. The three routes produce similar weight loss because the fraction that does get through ends up at a comparable steady state concentration.
Do oral GLP-1s make low dose protocols easier or harder?
Easier to start low, harder to fine tune, noisier day to day
Oral GLP-1s make a low starting dose easier to prescribe and a precise low dose harder to deliver. On the first point, both tablets are built around graded strengths that begin well below the therapeutic dose. Oral semaglutide starts at 1.5 mg and steps through 4 mg and 9 mg before the 25 mg maintenance dose, and the Rybelsus line for diabetes starts at 3 mg. Foundayo starts at 0.8 mg and rises through five further strengths. A prescriber who wants to hold someone at a starting or intermediate strength for months can do so with a standard prescription, no vial, no syringe, and no unit conversion, which removes the most common source of dosing error in compounded injectable protocols.
On the second point, a tablet only comes in the strengths the manufacturer makes. An injectable pen or a compounded vial can, under supervision, be set to a dose between the labelled steps. A tablet cannot, and neither oral GLP-1 can be split. The oral semaglutide tablet depends on the SNAC enhancer and the peptide releasing together in the stomach, and the label states it must be swallowed whole. Orforglipron is a coated single dose tablet with the same instruction. Anyone whose low dose strategy relies on small increments between steps, or on holding a dose that does not correspond to a tablet, will not find it in a pill.
The third difference is variability. A weekly injection produces a blood level that rises after the dose and falls gently over seven days, with little difference between one week and the next. Oral semaglutide is absorbed through a mechanism that depends on stomach contents, water volume, timing, and individual gastric physiology, and the day to day coefficient of variation in exposure is high, in the region of 50 to 100 percent in pharmacokinetic studies. Because semaglutide's half life is about a week, those daily swings are smoothed considerably at steady state, but a low tablet dose is still a less precise dose than the same average exposure delivered by injection. Orforglipron sits between the two: a daily tablet, but with conventional absorption and a one to two day half life, so its blood level is much steadier than oral semaglutide's.
How Steady Is the Blood Level on Each Route?
Illustrative relative plasma exposure over two weeks at steady state, each route indexed to an average of 100, showing the weekly injection sawtooth, the daily absorption noise of oral semaglutide, and the flatter profile of a small molecule
- Weekly injection
- Oral semaglutide daily
- Orforglipron daily
A constructed illustration, not measured data. The oral semaglutide line exaggerates the day to day absorption swing to make it visible; in practice the drug's one week half life buffers much of it, and what matters clinically is the average over several days. The shape is drawn from the published pharmacokinetic descriptions of each product rather than from any single study.
Are the side effects any different by mouth?
Same receptor, same nausea, one new question about the liver
The side effects of oral GLP-1s are the same in kind and roughly the same in frequency as the injections, because they come from the receptor rather than the route. In ATTAIN-1, nausea affected roughly 17 percent of participants at 6 mg, 24 percent at 12 mg, and 34 percent at 36 mg, against about 10 percent on placebo, and vomiting roughly 10, 14 and 24 percent against 3 percent. Discontinuation because of an adverse event ran from about 5 percent at the two lower doses to about 10 percent at the top dose, against under 3 percent on placebo. Those are approximate figures, and they sit in the same band as the semaglutide and tirzepatide phase 3 programmes at comparable weight loss.
The dose escalation logic is the same as for injectables. In ATTAIN-1 participants started at 1 mg and stepped up every four weeks, and most gastrointestinal events clustered around each step and faded within days. The same pattern held for oral semaglutide in OASIS 4, which escalated over 16 weeks. The reason slower escalation reduces nausea, covered in detail elsewhere on this site, applies equally to a tablet, and a tablet with more strengths gives a prescriber more places to pause.
The question that is specific to orforglipron is the liver. Small molecules are cleared by the liver in ways peptides are not, and Pfizer's danuglipron was dropped in 2025 after a participant developed drug induced liver injury that resolved on stopping. Orforglipron's phase 3 programme of more than 4,500 participants across the two registration trials reported no liver safety signal, and the FDA approved it without a liver warning. That is reassuring, and it is also a 72 week answer. Long term liver data for a small molecule GLP-1 will take years of post marketing surveillance to accumulate.
How Common Were Nausea, Vomiting, and Discontinuation in ATTAIN-1?
Approximate percent of participants reporting each outcome over 72 weeks by orforglipron dose
- Nausea
- Vomiting
- Stopped for adverse event
Approximate figures in the direction of the ATTAIN-1 safety reporting, rounded. Most events were mild or moderate and clustered around dose escalation steps. The 6 mg arm produced about 63 percent of the top dose weight loss with half the nausea and half the discontinuation rate, the same trade that appears at the low end of every GLP-1 dose curve.
Can a pill hold weight lost on an injectable?
The maintenance trial is the most relevant one for low dose thinking
A daily oral GLP-1 can hold most of the weight lost on an injectable, according to the one trial that tested it directly. ATTAIN-MAINTAIN enrolled adults who had already lost weight on injectable semaglutide 2.4 mg or tirzepatide and switched them, without a gap, to either orforglipron at one of several doses or to placebo for 52 weeks. Participants who moved to placebo regained a large share of what they had lost, the familiar pattern from every GLP-1 withdrawal study. Participants who moved to orforglipron held their weight, with small further losses at the higher doses and small regains at the lower ones. Full results were presented in 2025 and published in 2026.
This matters for low dose thinking because maintenance is where lower exposure has always made the most sense. The argument on this site has never been that a small dose produces the same loss as a large one. It is that once weight has come down, the exposure needed to hold it is lower than the exposure needed to get there, and that the trade between effect and side effects looks different in that phase. A tablet that a prescriber can step down through fixed strengths, without a fasting window in orforglipron's case, is a practical way to run that phase, and the maintenance trial is the first controlled evidence that a lower exposure oral step can do the job.
Two cautions. The trial switched people at full injectable doses to orforglipron doses that were not low, and the lowest orforglipron arms held weight less well than the highest. It did not test a microdose, and it did not test switching from a low injectable dose. What it established is the principle that route can change without losing the effect, and that daily oral maintenance after weekly injectable loss is a workable sequence. How low the oral dose can go in maintenance is not yet measured.
How Did the Four ATTAIN-1 Arms Separate Over 72 Weeks?
Illustrative percent change in body weight from baseline for placebo and the three orforglipron doses, anchored to the reported 72 week endpoints
- Placebo
- Orforglipron 6 mg
- Orforglipron 12 mg
- Orforglipron 36 mg
Constructed trajectories anchored to the approximate published endpoints, with intermediate points drawn to follow the typical shape of GLP-1 trial curves rather than taken from the trial's own timepoints. The 6 mg and 12 mg arms run close together throughout, which is consistent with the flattening that starts early on every GLP-1 dose curve.
What is worth knowing and raising with a prescriber?
Five points, none of which are a protocol
Everything below is context for a conversation rather than an instruction. Nothing here sets a dose, chooses a product, or replaces an assessment.
Oral semaglutide comes in 1.5, 4, 9 and 25 mg for weight management and 3, 7 and 14 mg as Rybelsus. Foundayo comes in six strengths starting at 0.8 mg. Those are the only oral doses that exist, and neither tablet can be split. A prescriber can hold any manufactured strength for as long as they judge appropriate, but a dose between strengths means an injectable.
The tablet is taken on waking with no more than about 120 mL of water and nothing else for 30 minutes, including coffee, other medicines, and supplements. Taking it with food or a full glass of water can cut absorption substantially, which turns a prescribed dose into a lower and less predictable one. Anyone who cannot reliably meet those conditions is a candidate for a different product, and that is a prescriber's call.
Both tablets step up every four weeks in the label, and most gastrointestinal events cluster around each step. The techniques that reduce nausea on an injectable, slower escalation, holding a step longer, smaller meals, apply unchanged. Route does not change the receptor, and a tablet is not a gentler way to reach the same exposure.
ATTAIN-MAINTAIN is the first controlled evidence that switching from injectable semaglutide or tirzepatide to a daily oral GLP-1 can hold weight over a year. It used orforglipron at doses that were not low, and it did not test switching from a low injectable dose, but it establishes that route can change without losing the effect. Whether and when to make that switch is a prescriber's decision.
Oral semaglutide's 30 minute window delays every other morning tablet, and its effect on gastric emptying can change the absorption of drugs with a narrow margin such as levothyroxine and warfarin, a point covered in more detail elsewhere on this site. Orforglipron has no fasting window but is metabolised by liver enzymes, and its label lists interactions to check. Either way the full medication list belongs in the conversation.
What is genuinely unresolved here?
Three gaps worth naming
Nobody has measured what a low oral dose does over a year in a large population. The lowest orforglipron arm in phase 3 was 6 mg, well up the dose curve, and the starting strengths of both tablets exist to manage side effects during escalation rather than as maintenance doses in their own right. The observation that 6 mg delivered 63 percent of the 36 mg effect is consistent with the front loaded shape seen across the class, and it is also the only low dose data point the programme produced. Everything below it is extrapolation.
Long term safety of a small molecule GLP-1 is a 72 week answer. Peptide GLP-1s have two decades of exposure data behind them, and their safety profile, including the pancreatitis, gallbladder, and thyroid C cell cautions, is well characterised. Orforglipron is a different chemical class cleared by a different route, and the danuglipron experience shows that liver signals in this family can appear rarely enough to be missed until late. The absence of a signal in 4,500 people over 72 weeks is a good result, and a limited one.
The head to head questions have not been asked. No trial has compared oral semaglutide with orforglipron, and no trial has compared either tablet against an injectable at matched exposure over the same period. The comparisons in this article are between separate trials with different populations, durations, and estimands, and a two point gap between two such trials is not a difference between two drugs. Whether one tablet suits low dose use better than the other is a question the current evidence cannot answer.
Frequently Asked Questions
Selected References
- Wadden TA, Yoo J, Halpern B et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity (ATTAIN-1). New England Journal of Medicine, 2025.
- Rosenstock J, Hsia S, Nevarez Ruiz L et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes (ACHIEVE-1). New England Journal of Medicine, 2025.
- Wharton S, Blevins T, Connery L et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity: a phase 2 randomised trial. New England Journal of Medicine, 2023.
- Frias JP et al. Orforglipron in adults with obesity and type 2 diabetes (ATTAIN-2). Lancet, 2025.
- Eli Lilly. ATTAIN-MAINTAIN: orforglipron for weight maintenance after injectable GLP-1 therapy. Presented at ObesityWeek 2025; full publication 2026.
- US Food and Drug Administration. Foundayo (orforglipron) prescribing information and approval, April 2026.
- Knop FK, Aroda VR, do Vale RD et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2023.
- Wharton S et al. Oral semaglutide 25 mg in adults with overweight or obesity (OASIS 4). New England Journal of Medicine, 2025.
- Wilding JPH, Batterham RL, Calanna S et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021.
- Aroda VR, Rosenstock J, Terauchi Y et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care, 2019.
- Buckley ST, Bækdal TA, Vegge A et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine, 2018. Mechanism of SNAC-mediated oral semaglutide absorption.
- Bækdal TA, Thomsen M, Kupčová V et al. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment, and related pharmacokinetic studies of dosing conditions. Journal of Clinical Pharmacology, 2018 to 2021.
- Kawai T, Sun B, Yoshino H et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proceedings of the National Academy of Sciences, 2020.
- Saxena AR, Frias JP, Brown LS et al. Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes. JAMA Network Open, 2023.
- Novo Nordisk. Wegovy (semaglutide) tablets prescribing information, December 2025.
This article is for general educational purposes only and does not constitute medical advice, diagnosis, treatment, or a recommendation to start, stop, switch, or change the dose of any medication. Oral semaglutide, orforglipron, and all other GLP-1 receptor agonists are prescription medicines, and the choice of product, dose, escalation schedule, and any low dose or microdosing approach should be decided and monitored by a qualified healthcare provider. Nothing here is intended to diagnose, prevent, treat, or cure obesity, diabetes, or any other condition, and no low dose or microdosing approach described in this article has been shown in trials to be safe or effective outside the specific trial conditions cited. Neither oral GLP-1 tablet should be split, crushed, or chewed, and the dosing conditions on each product label should be followed exactly. Several charts are constructed, interpolated, or illustrative rather than measured outcomes, and the figures cited are approximations of published reporting rather than exact values. Individual results vary.
Smaller Doses. Sharper Protocols.
Metabolic health you can measure, built around a dose designed to work with your body rather than against it.
Find Your Protocol